Deregulated expression of E2F1 promotes proteolytic degradation of tumor suppressor p73 and inhibits its transcriptional activity

Biochemical and Biophysical Research Communications

Volumn 387, Issue 1, 2009, Pages 143-148

  Ozaki, Toshinori ^a   Okoshi, Rintaro ^a   Ono, Sayaka ^a   Kubo, Natsumi ^a   Nakagawara, Akira ^a  

^a CHIBA CANCER CENTER   (Japan)

Author keywords

E2F1; MG 132; p73; Proteasome

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; COMPLEMENTARY DNA; CYCLOHEXIMIDE; LUCIFERASE; MESSENGER RNA; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN P73; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR E2F1;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; ENZYME ASSAY; GENETIC TRANSCRIPTION; HELA CELL; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LUNG CARCINOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CARCINOMA;

CELL LINE, TUMOR; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; E2F1 TRANSCRIPTION FACTOR; HUMANS; IMMUNOPRECIPITATION; NUCLEAR PROTEINS; PROTEASOME ENDOPEPTIDASE COMPLEX; RNA, MESSENGER; SEQUENCE DELETION; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 67651064269     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.06.141     Document Type: Article

References (22)

1. Ozaki T., and Nakagawara A. P73, a sophisticated p53 family member in the cancer world. Cancer Sci. 96 (2005) 729-737
2. Ikawa S., Nakagawara A., and Ikawa Y. P53 family genes: structural comparison, expression and mutation. Cell Death Differ. 6 (1999) 1154-1161
3. Flores E.R., Sengupta S., Miller J.B., Newman J.J., Bronson R., Crowley D., Yang A., McKeon F., and Jacks T. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 7 (2005) 363-373
4. De Laurenzi V., Costanzo A., Barcaroli D., Terrinoni A., Falco M., Annicchiarico-Petruzzelli M., Levrero M., and Melino G. Two new p73 splice variants, gamma and delta, with different transcriptional activity. J. Exp. Med. 188 (1998) 1763-1768
5. Pozniak C.D., Radinovic S., Yang A., McKeon F., Kaplan D.R., and Miller F.D. An anti-apoptotic role for the p53 family member, p73, during developmental neuron death. Science 289 (2000) 304-306
6. Stiewe T., Zimmermann S., Frilling A., Esche H., and Pützer B.M. Transactivation-deficient DeltaTA-p73 acts as an oncogene. Cancer Res. 62 (2002) 3598-3602
7. Grob T.J., Novak U., Maisse C., Barcaroli D., Lüthi A.U., Pirnia F., Hügli B., Graber H.U., De Laurenzi V., Fey M.F., Melino G., and Tobler A. Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ. 8 (2001) 1213-1223
8. Nakagawa T., Takahashi M., Ozaki T., Watanabe K., Todo S., Mizuguchi H., Hayakawa T., and Nakagawara A. Autoinhibitory regulation of p73 by Delta Np73 to modulate cell survival and death through a p73-specific target element within the Delta Np73 promoter. Mol. Cell. Biol. 22 (2002) 2575-2585
9. Zaika A.I., Slade N., Erster S.H., Sansome C., Joseph T.W., Pearl M., Chalas E., and Moll U.M. DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J. Exp. Med. 196 (2002) 765-780
10. La Thangue N.B. The yin and yang of E2F-1: balancing life and death. Nat. Cell Biol. 5 (2003) 587-589
11. Stevens C., and La Thangue N.B. E2F and cell cycle control: a double-edged sword. Arch. Biochem. Biophys. 412 (2003) 157-169
12. Irwin M., Marin M.C., Phillips A.C., Seelan R.S., Smith D.I., Liu W., Flores E.R., Tsai K.Y., Jacks T., Vousden K.H., and Kaelin W.G. Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature 407 (2000) 645-648
13. Stiewe T., and Putzer B.M. Role for the p53-homologue p73 in E2F-1-induced apoptosis. Nat. Genet. 26 (2000) 464-469
14. Koida N., Ozaki T., Yamamoto H., Ono S., Koda T., Ando K., Okoshi R., Kamijo T., Omura K., and Nakagawara A. Inhibitory role of Plk1 in the regulation of p73-dependent apoptosis through physical interaction and phosphorylation. J. Biol. Chem. 293 (2008) 8555-8563
15. Flemington E.K., Speck S.H., and Kaelin W.G. E2F-1-mediated transactivation is inhibited by complex formation with the retinoblastoma susceptibility gene product. Proc. Natl. Acad. Sci. USA 90 (1993) 6914-6918
16. Sherr C.J. Tumor surveillance via the ARF-p53 pathway. Genes Dev. 12 (1998) 2984-2991
17. Eymin B., Karayan L., Séité P., Brambilla C., Brambilla E., Larsen C.J., and Gazzéri S. Human ARF binds E2F1 and inhibits its transcriptional activity. Oncogene 20 (2001) 1033-1041
18. Nip J., Strom D.K., Eischen C.M., Cleveland J.L., Zambetti G.P., and Hiebert S.W. E2F-1 induces the stabilization of p53 but blocks p53-mediated transactivation. Oncogene 20 (2001) 910-920
19. Scheffner M., Huibregtse J.M., Vierstra R.D., and Howley P.M. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75 (1993) 495-505
20. Munarriz E., Bano D., Sayan A.E., Rossi M., Melino G., and Nicotera P. Calpain cleavage regulates the protein stability of p73. Biochem. Biophys. Res. Commun. 333 (2005) 954-960
21. Strachan G.D., Rallapalli R., Pucci B., Lafond T.P., and Hall D.J. A transcriptionally inactive E2F-1 targets the MDM family of proteins for proteolytic degradation. J. Biol. Chem. 276 (2001) 45677-45685
22. Moll U.M., Erster S., and Zaika A. P53, p63 and p73-solos, alliances and feuds among family members. Biochim. Biophys. Acta 1552 (2001) 47-59